Paritaprevir
Catalog No: 16060702
CAS Number: 1216941-48-8
Purity: 98% by HPLC
Paritaprevir, also known as ABT-450, is an acylsulfonamide inhibitor of the NS3-4A serine protease manufactured by Abbott Laboratories that shows promising results as a treatment of hepatitis C. When given in combination with ritonavir and ribavirin for 12 weeks, the rate of sustained virologic response at 24 weeks after treatment has been estimated to be 95% for those with hepatitis C virus genotype 1. Resistance to treatment with paritaprevir is uncommon, because it targets the binding site, but has been seen to arise due to mutations at positions 155 and 168 in NS3
For research use only. We do not sell to patients.
Chemical Information
| Name | Paritaprevir |
|---|---|
| Iupac Chemical Name | (2R,6S,13aS,14aR,16aS,Z)-N-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide |
| Synonyms | ABT-450 |
| Molecular Formula | C40H43N7O7S |
| Molecular Weight | 765.88 |
| Smile | C1(CC1)S(=O)(=O)NC(=O)[C@]12NC([C@H]3N(C([C@H](CCCCC\C=C/[C@@H]1C2)NC(=O)C2=NC=C(N=C2)C)=O)C[C@@H](C3)OC=3N=C2C=CC=CC2=C2C=CC=CC32)=O |
| InChiKey | UAUIUKWPKRJZJV-QPLHLKROSA-N |
| InChi | InChI=1S/C40H43N7O7S/c1-24-21-42-33(22-41-24)35(48)43-32-16-6-4-2-3-5-11-25-20-40(25,39(51)46-55(52,53)27-17-18-27)45-36(49)34-19-26(23-47(34)38(32)50)54-37-30-14-8-7-12-28(30)29-13-9-10-15-31(29)44-37/h5,7-15,21-22,25-27,32,34H,2-4,6,16-20,23H2,1H3,(H,43,48)(H,45,49)(H,46,51)/b11-5-/t25-,26-,32+,34+,40-/m1/s1 |
| CAS Number | 1216941-48-8 |
| Related CAS |
Ordering Information
| Packaging | Price | Availability | Purity | Shipping Time |
|---|---|---|---|---|
| Bulk | Enquiry | Enquiry | Enquiry |
| Formulation | Solid powder |
|---|---|
| Purity | 98% by HPLC |
| Storage | -20 ºC for 3 years |
| Solubility | Soluble in DMSO |
| Handling | |
| Shipping Condition | Shipped under ambient temperature |
| HS Code |
Coming soon.
| Targets | |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |
Not available
Chemical Structure
